Drug Profile
Lutetium-177 DOTA-Zoledronate - ITM Medical Isotopes GmbH
Alternative Names: DP-4411; ITM-41; n.c.a Lutetium-177 DOTA-Zoledronate; n.c.a. 177Lu-DOTA-Zoledronate; n.c.a. 177Lu-ZoledronateLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Johannes Gutenberg-University Mainz
- Developer ITM Medical Isotopes GmbH
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bone metastases; Osteosarcoma
Most Recent Events
- 27 Dec 2021 Lutetium- 177 DOTA-Zoledronate licensed to Grand Pharmaceutical in mainland China, Hong Kong, Macau and Taiwan
- 21 Dec 2021 ITM Isotope Technologies and Australian Nuclear Science and Technology Organisation agrees on licensing and supply agreement for N.c.a. 177Lu
- 01 Oct 2021 Phase-I development in Bone metastases is ongoing in Germany (Isotopen Technologien Munchens pipeline, October 2021)